398 studies on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 12,755 published Tirzepatide COA source records from third-party laboratories, covering 1,778 publicly attributable vendor identities. Across 11,835 records with positive numeric purity, the arithmetic mean is 99.68%. 143 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 25 positive purity results are below 90%; 598 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-17. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-19, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $6.50 | $5.50–$7.50 | $1.30 | 2 sources · 2 offers |
| 10 mg | $8.88 | $8.00–$9.50 | $0.89 | 4 sources · 4 offers |
| 15 mg | $9.67 | $8.50–$10.50 | $0.64 | 3 sources · 3 offers |
| 20 mg | $11.33 | $10.50–$12.00 | $0.57 | 3 sources · 3 offers |
| 30 mg | $15.00 | $12.50–$17.00 | $0.50 | 4 sources · 4 offers |
| 40 mg | $19.88 | $18.00–$23.00 | $0.50 | 4 sources · 4 offers |
| 50 mg | $22.25 | $22.00–$22.50 | $0.45 | 2 sources · 2 offers |
| 60 mg | $26.12 | $25.00–$27.50 | $0.44 | 4 sources · 4 offers |
| 100 mg | $35.00 | $35.00–$35.00 | $0.35 | 1 source · 1 offer |
| 120 mg | $37.00 | $37.00–$37.00 | $0.31 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-17. Aggregate calculated: 2026-10-19T07:42:26.816400+00:00. Calculation time is not a laboratory observation date.
Within that total, 3068 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 241 | 99.6% | 0 of 229 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified | Reveal with Pro → | |
| #2 | 195 | 99.53% | 0 of 183 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified | Reveal with Pro → | |
| #3 | 136 | 99.78% | 0 of 96 (0.0%) 0 0% / not detected · 0 wrong compound · 40 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120707 (99.88%) · #120652 (99.93%) · #120647 (99.96%) · #120646 (99.94%) · #120710 (99.95%) · #120632 (99.9%)
The pervasive and devastating impact of addiction, affecting billions globally and incurring significant health, social, and economic costs, underscores the critical need for innovative treatment strategies. Incretin-…
A deeper understanding of the precise mechanisms underlying beta-cell stress and identity failure is absolutely crucial for the development of novel, disease-modifying therapeutic strategies for type 2 diabetes. This …
This pilot study holds significant promise, as successful integration of weight management strategies could potentially improve treatment efficacy and long-term outcomes for endometrial cancer patients. If tirzepatide…
This pilot study is crucial for understanding Tirzepatide's potential as a targeted therapy for MASLD, a condition with limited effective treatment options. Positive findings could pave the way for larger, more defini…
Finding effective strategies to prevent weight regain after discontinuing GLP-1 agonists is critically important for long-term obesity management and patient well-being. This trial could provide evidence for new stand…
This Phase II trial is significant because it addresses a critical unmet need for effective weight management in adult survivors of childhood Acute Lymphoblastic Leukemia (ALL), a group highly susceptible to cardiomet…
This trial is critically important because it addresses a significant gap in our understanding of how tirzepatide performs in a vulnerable and growing patient group. The findings could establish a new therapeutic opti…
This study addresses a critical need for practical, accessible dietary recommendations to complement GLP-1 RA therapy, potentially enhancing patient outcomes beyond just weight loss. If successful, it could provide a …
This clinical trial is profoundly significant as it explores a novel and promising therapeutic approach for ADPKD, a disease with limited treatment options and a high burden on patients. If successful, this research c…
If successful, this pilot study could pave the way for a novel pre-surgical intervention to improve outcomes for prostate cancer patients. Demonstrating the feasibility of tirzepatide-assisted weight loss could lead t…
Had it been completed, this registry would have provided an invaluable real-world dataset for understanding the long-term trajectory of obesity and metabolic diseases, offering insights into how these conditions evolv…
If tirzepatide proves safe and effective, it could represent a significant therapeutic advancement for individuals with Type 1 Diabetes who struggle with obesity or overweight. Currently, there are limited pharmacolog…
The initiation of this Phase IV trial is a significant step, as it explores a novel therapeutic avenue for Idiopathic Intracranial Hypertension (IIH), a condition with limited effective treatments. Tirzepatide, known …
This trial represents a paradigm shift in Type 1 Diabetes management, potentially transforming daily life for millions by simplifying insulin delivery and reducing mental burden. If successful, tirzepatide could enabl…
Obesity-related male infertility is a growing concern, and current treatments often lack sustained efficacy or adherence. This trial holds the potential to identify a novel and effective pharmacological intervention f…
This case report holds significant clinical importance as it expands the known adverse event profile of Tirzepatide, alerting clinicians to the possibility of drug-induced liver injury. While such events are rare, rec…
While specific numerical outcomes from this completed trial (NCT03882970) are not detailed in the provided record, the study's primary objective was to demonstrate the superior efficacy of tirzepatide in improving gly…
This research holds significant promise as tirzepatide could represent an innovative approach to effectively induce weight loss and inhibit tumor growth in obesity-driven endometrial cancer. Given the strong link betw…
This case report is significant as it contributes to the emerging understanding of tirzepatide's potential adverse effects, specifically hepatotoxicity. The finding highlights the importance for clinicians to consider…
If BGM0504 demonstrates comparable or superior efficacy and safety to Tirzepatide, it could represent a significant advancement in the treatment landscape for obesity. A new therapeutic option would provide clinicians…
The termination of this Phase 2 study means a potential avenue for enhanced obesity treatment in older adults remains unexplored. While tirzepatide is highly effective, combination therapies are often sought to improv…
This Randomized Control Trial is highly significant as it explores a novel strategy to enhance the effectiveness of bariatric surgery, potentially offering a more robust solution for severe obesity. If successful, com…
The findings from this trial could have a profound impact on the treatment landscape for Type 2 Diabetes. If CagriSema demonstrates superior or even comparable efficacy with a favorable safety profile, it could become…
The potential success of this combination therapy could represent a significant advancement in the treatment landscape for obesity and overweight. By potentially enhancing the already impressive effects of tirzepatide…
This pilot study is significant because it explores a novel adjunctive therapeutic strategy for Crohn's disease by targeting metabolic health and weight. If successful, it could demonstrate that GIP/GLP-1 receptor ago…
Understanding the precise mechanisms by which Tirzepatide impacts pancreatic alpha and beta cell function and insulin sensitivity is critically important. This mechanistic insight can refine our understanding of optim…
The withdrawal of this study means a potential avenue for exploring enhanced weight loss and metabolic improvements, particularly through muscle preservation with Bimagrumab alongside Tirzepatide's established effects…
Persistent obesity after bariatric surgery represents a significant clinical challenge, often leading to comorbidities and reduced quality of life. If Tirzepatide proves effective and safe in this specific patient pop…
This foundational Phase 1 study is crucial for the development of tirzepatide, providing essential data on its pharmacokinetics and safety in humans. Understanding how the drug is absorbed, distributed, metabolized, a…
This pilot study is critically important as it addresses a significant unmet medical need for safe and effective weight management in obese kidney transplant recipients. Successful outcomes could establish Tirzepatide…
Understanding the extrapancreatic effects of GIP and GLP-1 is crucial for optimizing current and developing future treatments for type 2 diabetes and obesity. This research will provide critical insights into why comb…
Free, no account — handy when you're working with Tirzepatide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account